NCT05976893 2023-08-04
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Xinjiang Medical University
Phase 4 Unknown
Xinjiang Medical University
University Health Network, Toronto
VA Office of Research and Development